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Abstract
Importance—Postnatally acquired cytomegalovirus (CMV) is typically benign in term infants 
but, in very low birth weight (VLBW) infants, can cause pneumonitis and sepsis-like illness. 
Whether postnatal CMV infection results in long-term pulmonary sequelae in these infants is 
unknown.
Objective—To investigate the relationship between postnatal CMV infection and 
bronchopulmonary dysplasia (BPD) and mortality in a large, multicenter cohort of VLBW infants.
Design—Propensity-matched retrospective cohort study.
Setting—348 neonatal intensive care units in the United States from 1997–2012.
Participants—Hospitalized VLBW (<1500 g) infants.
Exposures—Postnatal CMV infection was defined as a diagnosis of CMV or detection of CMV 
from blood, urine, cerebrospinal fluid, or respiratory secretions on or after day of life 21. Infants 
with a CMV diagnosis or virologic detection of CMV prior to day of life 21 were not considered 
to have postnatal infection.
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Main Outcomes and Measures—We matched infants with postnatal CMV infection 1:1 to 
comparison infants using propensity scores, and used Poisson regression to examine the effect of 
postnatal CMV on the combined risk of death or BPD at 36 weeks postmenstrual age. To describe 
features of postnatal CMV infection, we extracted clinical and laboratory data from 7 days before 
until 7 days after infants met criteria for postnatal CMV.
Results—Of 101,111 infants, 328 (0.3%) had postnatal CMV infection. We matched a 
comparison infant to 303 (92%) CMV-infected infants for a final cohort of 606 infants. The 
median gestational age and birth weight of this cohort were 25 weeks and 730 g, respectively. 
Postnatal CMV infection was associated with an increased risk of death or BPD at 36 weeks 
postmenstrual age (risk ratio [RR]: 1.21, 95% confidence interval [CI]: 1.10–1.32) and BPD (RR: 
1.33, 95% CI: 1.19–1.50). Changes in cardiorespiratory status associated with postnatal CMV 
infection included a new requirement for vasopressor medications (9%), intubation for mechanical 
ventilation (15%), a new oxygen requirement (28%), and death (1.2%).
Conclusions and Relevance—In VLBW infants, postnatal CMV infection was associated 
with increased risk of BPD. Further studies are needed to determine the role of preventative 
measures against CMV in this population.
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Cytomegalovirus (CMV) is the most common perinatal viral infection worldwide.1 CMV 
may be acquired in utero (congenital CMV infection), at delivery from exposure to maternal 
genital secretions, or after birth (postnatal CMV infection).2-4 Postnatal infection among 
infants most frequently results from exposure to virus shed in breast milk and – prior to 
widespread use of CMV-negative and leukoreduced blood products in premature infants – 
through blood transfusion.3-6 Postnatal infection is not typically associated with clinical 
signs in term infants, likely as a result of the relative maturity of the term infant immune 
system and maternal antibody acquired during the third trimester.7,8 In contrast, very low 
birth weight (VLBW; birth weight <1500 g) infants with postnatal CMV infection can 
manifest sepsis-like illness, pneumonitis, hepatitis, or hematological abnormalities.2,6,9 
Although many VLBW infants with clinically apparent postnatal CMV experience a 
deterioration in respiratory status coinciding with infection, it is unclear if this results in 
long-term pulmonary sequelae such as bronchopulmonary dysplasia (BPD).
In this study, we investigate the relationship between postnatal CMV infection and BPD and 
mortality in a large, multicenter cohort of VLBW infants. As a secondary objective, we 
describe the clinical and laboratory characteristics associated with postnatal CMV infection 
in this cohort to inform diagnostic testing in VLBW infants.
METHODS
STUDY SETTING
We identified VLBW infants hospitalized on day of life (DOL) 21 in neonatal intensive care 
units (NICU) managed by the Pediatrix Medical Group from 1997–2012. Data were 
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obtained from an electronic medical record that prospectively captures information from 
daily progress notes generated by clinicians using a computer-assisted tool. The method of 
data extraction was previously described in detail.10 During the study period, the Pediatrix 
Medical Group included 348 NICUs in the United States. Data on multiple aspects of patient 
care are available, including demographics, medications, laboratory and culture results, and 
diagnoses. This study was approved by the Duke University Institutional Review Board.
POSTNATAL CMV INFECTION
We defined postnatal CMV infection as a diagnosis of “CMV infection,” “acquired CMV 
infection,” or “congenital CMV infection,” or detection of CMV by culture or polymerase 
chain reaction (PCR) of blood, urine, cerebrospinal fluid, or respiratory secretions on or 
after DOL 21. To limit identification of infants who were infected congenitally, infants were 
not considered to have postnatal CMV if they had a diagnosis of “intracranial calcifications” 
or any of the following prior to DOL 21: 1) detection of CMV by culture or PCR from any 
source; 2) a diagnosis of “CMV infection,” “acquired CMV infection,” or “congenital CMV 
infection”; 3) a diagnosis of “microcephaly”; 4) treatment with ganciclovir, valganciclovir, 
cidofovir, or foscarnet; or 5) a transaminitis, defined as aspartate transaminase (AST) >150 
U/L and alanine aminotransferase (ALT) >90 U/L. For the purposes of this analysis, only 
postnatal CMV infections occurring at <36 weeks postmenstrual age were included.
OUTCOMES
The primary outcome was death or BPD at 36 weeks postmenstrual age. Secondary 
outcomes were BPD and death prior to hospital discharge, considered separately. Infants 
were classified as having BPD if they received respiratory support (nasal cannula oxygen or 
continuous positive airway pressure [CPAP], conventional mechanical ventilation, or high-
frequency ventilation) continuously from a postmenstrual age of 36 0/7 to 36 6/7 weeks.11 
Infants on room air without any respiratory support for at least one day between 36 0/7 and 
36 6/7 weeks postmenstrual age were classified as not having BPD. Infants discharged prior 
to 36 6/7 weeks postmenstrual age who did not receive respiratory support on the day of 
discharge were classified as not having BPD. The outcome of BPD was considered missing 
for infants who died before 36 6/7 weeks postmenstrual age or were discharged prior to 36 
6/7 weeks postmenstrual age and received respiratory support on the day of discharge.
OTHER DEFINITIONS
We defined small-for-gestational-age as birth weight below the tenth percentile for 
gestational age (GA), based on Olsen growth curves.12 Sepsis was defined as isolation of 
one or more bacterial or fungal pathogens from blood. We excluded likely bacterial 
contaminants, including non-speciated streptococci, Bacillus spp., Corynebacterium spp., 
and Micrococcus spp. We divided coagulase-negative Staphylococcus infections into three 
categories: definite, probable, and possible, as previously described.13 Only definite and 
probable infections were included in this analysis. We considered the following medications 
to be vasopressors: amrinone, dobutamine, dopamine, epinephrine, milrinone, and 
norepinephrine. We defined neutropenia as an absolute neutrophil count <1500 cells/μL, 
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thrombocytopenia as a platelet count <100,000/µL, and direct hyperbilirubinemia as a serum 
direct bilirubin >1.0 mg/dL.
STATISTICAL ANALYSES
We compared outcomes among VLBW infants with postnatal CMV infection to infants 
without postnatal CMV. Infants without postnatal CMV infection were selected from all 
VLBW infants hospitalized on DOL 21 who did not meet criteria for postnatal CMV, 
including infants who were not tested for CMV and infants who tested negative for CMV. 
Because postnatal CMV infection is more likely to be associated with clinical signs among 
the subset of VLBW infants with extreme prematurity and significant comorbidities,2 we 
used propensity score matching to obtain similar populations for comparison. Comorbid 
conditions and surrogates for severity of illness were assessed in relation to DOL 21, the day 
on which infants were first at risk for postnatal CMV infection. We included the following 
variables, including previously reported risk factors for BPD, in a logistic regression model 
to generate propensity scores: GA; birth weight; small-for-gestational-age status; sex; race; 
discharge year; NICU site; days of breast milk exposure between DOL 15 and 21; number of 
days on which surfactant was received; necrotizing enterocolitis, grade III or IV 
intraventricular hemorrhage, patent ductus arteriosus, and sepsis episode occurring on DOL 
≤21; and number of vasopressor medications, type of respiratory support, and fraction of 
inspired oxygen (FiO2) assessed on DOL 21.14 We included discharge year as a categorical 
variable in the model to adjust for changes in clinical practice and outcomes over time. We 
matched 1:1 on the propensity score using nearest-neighbor matching, provided that the 
difference in the propensity scores of infants with postnatal CMV and their matched 
comparison infants was <0.01.15 We examined the distributions of propensity scores across 
groups using histograms and kernel density plots. We assessed covariate balance across 
groups within both the unmatched and propensity score-matched cohorts using chi-square 
tests.
We used Poisson regression with a sandwich variance estimator conditioning on the 
matched pair to determine the effect of postnatal CMV infection on outcomes in the 
propensity score-matched cohort.16 This modeling approach, as opposed to logistic 
regression, was appropriate because the odds ratio obtained using logistic regression is an 
upwardly biased estimate of the risk ratio (RR) when the outcome is not rare (>10%), as was 
the case for our primary outcome and secondary outcome of BPD.17
We conducted sensitivity analyses to assess whether our findings would have differed had 
alternative assumptions been made. First, we examined the effect of postnatal CMV 
infection on outcomes when infants meeting criteria for postnatal CMV based only on 
diagnostic coding (and not virologic data) were excluded (n=106). In originally defining 
postnatal CMV infection, we included infants with a diagnosis of “congenital CMV 
infection” on or after DOL 21 because we felt that the distinction between congenital and 
postnatal CMV infection may not be accurately assessed. Our second sensitivity analysis 
thus excluded infants with a diagnosis of “congenital CMV infection” on or after DOL 21 
(n=135). Finally, to assess whether the observed association of postnatal CMV with BPD 
might be related to a transient respiratory deterioration associated with acute CMV infection, 
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we repeated analyses excluding postnatal CMV infections occurring at ≥34 weeks 
postmenstrual age (n=94). In conducting each of these sensitivity analyses, we first excluded 
children who met the specified condition, and then repeated the procedures for generating 
propensity scores and matching comparison infants to infants with postnatal CMV by 
propensity scores.
To describe the features of postnatal CMV infection, we extracted clinical and laboratory 
data from 7 days before until 7 days after infants met criteria for postnatal CMV. For each 
variable, we calculated the maximum (or minimum) value recorded during the time period. 
We also determined the proportion of infants who died during this time period or required 
initiation of vasopressor medications, increased level of respiratory support or intubation, 
and increased FiO2 or initiation of supplemental oxygen on one or more days. All statistical 
analyses were conducted using STATA version 13.1 (College Station, TX).
RESULTS
PATIENT CHARACTERISTICS
We identified 101,111 VLBW infants, and 328 (0.3%) infants met study criteria for 
postnatal CMV infection (Figure 1). Of these infants, 144 (44%) met criteria for postnatal 
CMV based on diagnosis and virologic testing, 106 (32%) based on diagnosis only, and 78 
(24%) based on virologic testing only. The sources of specimens for the 222 infants with 
virologic testing were urine (72%), trachea (12%), blood (8%), and nasopharynx (8%). We 
matched a comparison infant to 303 of 328 (92%) infants with postnatal CMV infection. For 
the remaining 25 infants with postnatal CMV, data were missing for one or more variables 
included in the model to generate propensity scores. The 606 infants in the final propensity 
score-matched cohort were from 70 NICU sites. Propensity score matching resulted in a 
population that was closely matched on baseline characteristics, with no statistically 
significant differences in covariates observed across the two groups (Table 1). Median (25th 
percentile, 75th percentile) GA and birth weight of infants in the propensity score-matched 
cohort were 25 weeks (24–27) and 730 g (611–915), respectively.
OUTCOMES
In the propensity score-matched cohort, infants with postnatal CMV infection were 
discharged (or died) at a median of 40.6 weeks postmenstrual age. Infants without postnatal 
CMV infection were discharged (or died) at a median of 38.6 weeks postmenstrual age. 
Primary and secondary outcomes by postnatal CMV infection status in this cohort are shown 
in Table 2. Overall, 69% of infants died or met criteria for BPD at 36 weeks postmenstrual 
age, including 76% of infants with postnatal CMV infection and 63% of infants without 
postnatal CMV. Postnatal CMV infection was associated with an increased risk of death or 
BPD at 36 weeks postmenstrual age (RR: 1.21, 95% confidence interval [CI]: 1.10–1.32) 
and BPD (RR: 1.33, 95% CI: 1.19–1.50). There was no significant association between 
postnatal CMV and death prior to hospital discharge (RR: 0.71, 95% CI: 0.43–1.15). The 
effect of postnatal CMV infection on primary and secondary outcomes was substantively 
unchanged in sensitivity analyses (eTable 1).
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CLINICAL AND LABORATORY CHARACTERISTICS OF POSTNATAL CMV INFECTION
Median (25th percentile, 75th percentile) GA and birth weight of the 328 infants with 
postnatal CMV infection were 25 (24–27) weeks and 730 (618–903) g. Median (25th 
percentile, 75th percentile) postnatal age at CMV diagnosis was 49 (38–60) days (Table 3). 
We observed one or more changes in cardiorespiratory status or laboratory abnormalities in 
293 (89%) infants within 7 days before or after CMV diagnosis. Changes in 
cardiorespiratory status included a new requirement for vasopressor medications (9%), 
intubation for mechanical ventilation (15%), a new oxygen requirement (28%), and death 
(1.2%). Among infants with available data, thrombocytopenia (66%), direct 
hyperbilirubinemia (66%), and neutropenia (34%) were the most frequent laboratory 
abnormalities.
DISCUSSION
We present findings from the largest reported cohort of VLBW infants with postnatal CMV 
infection to date. Our results indicate that postnatal CMV infection at <36 weeks 
postmenstrual age is associated with an increased risk of BPD. Postnatal CMV was not 
associated with death before hospital discharge.
There are several plausible mechanisms by which postnatal CMV infection might increase 
the risk of BPD. Damage to lung tissue may occur as a direct result of viral infection or 
indirectly through the immune response to the virus.18 Infection of the lung by CMV is 
characterized by a mononuclear inflammatory process, deposition of fibrin, hemorrhage, and 
sloughing of lung epithelial cells.19 CMV might also increase BPD risk by causing a 
deterioration in respiratory status that leads to increased exposure to other known risk 
factors, such as prolonged mechanical ventilation.
A potential association between postnatal CMV and BPD was first observed in the 1970’s. 
Whitley et al. described two infants who developed a protracted pneumonitis with 
histopathology suggesting a causative role for CMV.20 Roughly 10 years later, investigators 
reported radiographic findings consistent with BPD in 24 of 32 (75%) infants diagnosed 
with postnatal CMV infection compared with 12 of 32 (38%) controls in a single center 
study.21 Other case reports have since attributed multicystic lung disease, interstitial fibrosis, 
and pulmonary hypertension to postnatal CMV infection.22,23
However, postnatal CMV infection was not associated with BPD in several recent 
prospective studies. In contrast to earlier studies, these cohorts identified incident CMV 
infections through serial virologic monitoring, and the majority of the identified infections 
were not clinically apparent. Neuberger et al. monitored the premature infants of CMV-
seropositive mothers with biweekly CMV culture and PCR of urine, comparing the clinical 
course of 40 infants with postnatal CMV infection to matched controls. They found no 
association between postnatal CMV and BPD, although the overall incidence of BPD was 
low (16%).24,25 Nijman et al. prospectively screened 315 infants born at <32 weeks GA, 
identifying 39 infants with postnatal CMV infection. BPD, defined in this study as the 
requirement for FiO2 ≥30% or positive pressure ventilation at 36 weeks postmenstrual age, 
was diagnosed in 0% of infants with postnatal CMV infection and 2% of infants without 
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postnatal CMV.26 Eighty-five percent of infants in this cohort did not have clinical signs or 
laboratory abnormalities that could be attributed to CMV infection.26 Finally, Prosch et al. 
collected urine samples and tracheal or pharyngeal aspirates from 66 VLBW infants during 
the first month of life. BPD developed in 12% of non-CMV-infected infants and 29% of 
infants with CMV infection, including 3 of 4 (75%) infants with postnatal infection.27 There 
were no significant differences in the prevalence of BPD by CMV infection status, although 
the small number of postnatally infected infants precluded specific comparisons with this 
group.27
The incidence of postnatal CMV infection in our cohort was lower than was reported in 
most prior studies. In a recent meta-analysis of 17 studies, the risk of postnatal CMV 
infection among VLBW infants in the United States was estimated to be 6.5%, with 1.4% of 
infants developing a sepsis-like syndrome.28 Only 0.3% of VLBW infants in our cohort met 
criteria for postnatal CMV infection at <36 weeks postmenstrual age. This comparatively 
low incidence likely reflects non-recognition of postnatal CMV infections associated with 
no or few clinical signs. Specifically, we identified infants with postnatal CMV infection 
based on physician diagnoses or virologic testing in a non-research setting. Although CMV 
screening practices at our NICU sites were unavailable, few NICUs in the United States 
were routinely screening for postnatal CMV infection during the study period. Thus, the 
majority of CMV-infected infants identified in our cohort had clinical signs or laboratory 
abnormalities consistent with postnatal infection. Moreover, establishing a diagnosis of 
postnatal CMV in practice is challenging, even in the presence of clinical signs, given 
substantial overlap with the presentation of bacterial or fungal sepsis. Hence, many of the 
postnatal CMV infections in our cohort may further represent the small minority of 
infections that result in severe or protracted symptoms. While our identification of infants 
with postnatal CMV reflects standard practice in most NICUs during the study period, our 
findings may not be generalizable to settings that routinely screen VLBW infants for CMV. 
Large prospective studies are needed to determine whether CMV acquisition without clinical 
signs is associated with BPD.
The clinical signs and laboratory abnormalities associated with postnatal CMV infection in 
our cohort were generally similar to those previously reported in smaller studies.2,6,29 
Notably, however, direct hyperbilirubinemia and thrombocytopenia were substantially more 
common in our cohort than in prior studies. While these results may accurately reflect the 
true prevalence of these findings in clinically apparent postnatal CMV infections, it is also 
possible that these laboratory abnormalities prompt clinicians to consider CMV infection in 
VLBW infants.
Breast milk has established nutritive and immunological benefits and reduces the incidence 
of late-onset sepsis and necrotizing enterocolitis in premature infants.30,31 However, with 
the practice of transfusion of CMV-seronegative or leukoreduced blood, breastfeeding is 
also the primary route of CMV acquisition among infants in the United States.5 Up to half of 
pregnant mothers are CMV-seropositive, and over 80% of these mothers shed CMV in their 
breast milk.32-34 Pasteurization of breast milk eliminates infectious virus but diminishes the 
beneficial properties of the milk, while freezing reduces but does not eliminate CMV 
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transmission.34-36 Our study suggests that alternative strategies are needed to prevent CMV 
transmission to VLBW infants while preserving the beneficial properties of breast milk.
Our study has a number of limitations, most of which relate to the retrospective 
observational design. First, criteria for postnatal CMV infection were based on virologic 
testing and physician diagnoses in a non-research setting. As a result, the vast majority of 
infants in our cohort had signs of CMV infection, which generally represents only 10-33% 
of infections among VLBW infants.26,28,29 Second, given that most congenital CMV 
infections are not associated with clinical signs and that prolonged urinary shedding and 
viremia are common, some infants in our cohort may have had congenital infections.37 To 
minimize this possibility, we excluded infants with CMV-related diagnoses, characteristic 
laboratory abnormalities, or treatment with antivirals with activity against CMV prior to 
DOL 21. Moreover, pneumonitis is infrequent among infants with congenital infection, so 
misclassification would tend to bias our results toward the null.18 We did not consider BPD 
and death in a single model as competing risk events, choosing instead to examine the effect 
of postnatal CMV on a composite outcome variable. Finally, we cannot exclude the 
possibility of unmeasured confounding variables. However, infants with CMV were closely 
matched to comparison infants on other known risk factors for BPD, including all variables 
that predicted risk of BPD in a recent multicenter study.38
Among VLBW infants, postnatal CMV infection was associated with an increased risk of 
BPD. Further research is needed to define the long-term sequelae of postnatal CMV on 
pulmonary and neurological outcomes and develop novel CMV prevention measures to 
permit safe breast milk feeding by VLBW infants.
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Table 2
Outcomes of VLBW Infants According to Postnatal CMV Infection, Propensity Score-Matched Cohort 
(n=606)
Postnatal CMV (n=303) No Postnatal CMV 
(n=303)
Adjusted RR (95% CI) P
Primary outcome
 Death or BPD at 36 weeks postmenstrual age 76% 63% 1.21 (1.10, 1.32) <0.001
Secondary outcomes
 BPD 71% 53% 1.33 (1.19, 1.50) <0.001
 Death prior to hospital discharge 8% 11% 0.71 (0.43, 1.16) 0.17
Abbreviations: VLBW, very low birth weight; CMV, cytomegalovirus; RR, risk ratio; CI, confidence interval; BPD, bronchopulmonary dysplasia.
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Table 3
Clinical and Laboratory Characteristics of VLBW Infants with Postnatal CMV Infection (n=328)
Postnatal CMVa (n=328)









 Received ≥1 vasopressor medications 12%
 New requirement for vasopressor medications 9%
 Maximum level of respiratory support
  Room air 6%
  Nasal cannula oxygen or CPAP 32%
  Conventional mechanical ventilation 45%
  High-frequency ventilation 18%
 Required increased level of respiratory support 25%
 Required intubation for mechanical ventilation 15%
 Maximum FiO2
  21% 8%
  22–50% 51%
  51–100% 41%
 Required increased FiO2 58%
 New oxygen requirement 28%
 Death 1.2%
Laboratory abnormalities
 Absolute neutrophil count <1500 cells/μL 34%
 Absolute lymphocyte count <2500 cells/μL 26%
 Platelet count <100,000/μL 66%
 Transaminitisb 16%
 Direct bilirubin >1.0 mg/dL 66%
Change in cardiorespiratory status or laboratory abnormality 89%
Abbreviations: VLBW, very low birth weight; CMV, cytomegalovirus; CPAP, continuous positive airway pressure; FiO2, fraction of inspired 
oxygen; μL, microliter; mg, milligram; dL, deciliter.
a
Percentages may not sum to total because of rounding.
b
Defined as aspartate transaminase (AST) >150 U/L and alanine aminotransferase (ALT) >90 U/L.
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